In a clinical trial with nearly 1,000 participants, people on resmetirom were more likely to see improvement in their condition than those taking a placebo, researchers reported in the New England Journal of Medicine
K.PatelP
Additional risk factors include pre-existing gastroparesis, diabetes-related autonomic neuropathy, Parkinson disease, connective tissue disorders affecting gastrointestinal motility, and concurrent use of medications known to slow gastric emptying
Chemical composition, functional properties and processing of carrot-a review
Retrieved from Moon, J., Koh, G
In a yearlong Phase 3 trial, the highest dose of Lilys pill, orforglipron, lowered a measure of blood sugar called A1C by 1.9 percentage points, while the highest dose of Novos drug, marketed as Rybelsus, lowered A1C by 1.5 percentage points, when analyzing all patients regardless of discontinuations